Is United Therapeutics Corp (UTHR) a risky stock?
As of July 21, 2026, Clavix grades United Therapeutics Corp (UTHR) B for risk, a composite score of 81 out of 100 on an A+ to F scale, which puts UTHR in the "low risk" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind UTHR's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how UTHR scores on each, as of July 21, 2026.
What's moving UTHR's risk right now
Company-specific signals Clavix flags behind UTHR's current grade, drawn from recent news and filings as of July 21, 2026.
A rival's lung-drug YUTREPIA is expanding after a favorable court outcome, putting pressure on United Therapeutics' sales and pricing in its core pulmonary hypertension business.
Bank of America lowered its UTHR price target by about 1.1%, a small cut suggesting the rating sees the stock as roughly fairly priced with limited near-term upside.
Analysts say United Therapeutics trades below estimated fair value and has delivered strong past returns, though investors need to weigh how much of its future growth is already built into the price.
What a B grade means
On the Clavix A+ to F scale, UTHR's composite of 81 falls in the A band (80–100), read as "low risk." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell UTHR or any security. Grades are risk indicators, not predictions of return. Data may be delayed.